Ligand validation:2R4U

PE3: 3,6,9,12,15,18,21,24,27,30,33,36,39-TRIDECAOXAHENTETRACONTANE-1,41-DIOL

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2R4U_PE3_A_504	20%	83%	0.126	0.85	0.58	0.22	-	-	0	0	30%	0.3023
2R4U_PE3_A_505	8%	85%	0.199	0.825	0.5	0.24	-	-	0	0	12%	11.63
2R4U_PE3_A_506	6%	89%	0.23	0.821	0.52	0.13	-	-	0	0	14%	13.950000000000001
2R4T_PE3_A_513	18%	82%	0.143	0.894	0.48	0.33	-	-	0	0	7%	6.98
4Y5D_PE3_A_201	34%	36%	0.135	0.879	1.15	1.36	2	5	15	0	65%	0.6512
2VFX_PE3_C_1210	32%	71%	0.107	0.916	0.5	0.6	-	-	0	0	23%	0.2326
5DHD_PE3_A_808	30%	71%	0.095	0.916	0.43	0.67	-	-	2	0	12%	11.63
6MGJ_PE3_D_802	29%	62%	0.133	0.917	0.56	0.88	-	-	0	0	30%	0.3023
4F9Z_PE3_B_301	24%	39%	0.164	0.906	0.71	1.63	-	2	3	0	37%	0.3721

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.